Nordion Inc. announced an additional randomized, multicenter phase 3 clinical trial for TheraSphere, a treatment for liver cancer.
The trial, YES-P, will focus primarily in Europe and is aiming for enrollment of about 350 patients. The trial will continue to evaluate the safety and efficacy of TheraSphere in the treatment of patients with portal vein thrombosis (PVT) associated with unresectable hepatocellular carcinoma.
While the presence of PVT is a contraindication for most embolic therapies, TheraSphere represents a safe alternative.
The trial will follow a 2-armed design. In 1 arm, patients will receive Y-90 radioembolization treatment with TheraSphere, and patients in the other arm will be treated with sorafenib.
Source: Nordion.